Go to Top

Rosetta Genomics (ROSG): Published Study of microRNA characteristics of CUP tumors

Rosetta Genomics is a leading molecular diagnostics company advancing molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of five cancer tests since the beginning of 2009, the Company is now working to develop additional tests in the cancer realm and in other fields.

Rosetta Genomics today announced results from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis.

The study assessed microRNA differences between CUP metastases with favorable prognosis and metastases of known primary tumors in order to screen for an aggressive, pro-metastatic, CUP-specific biologic signature.

This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries.

George Pentheroudakis, M.D., Department of Medical Oncology

This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients. We look forward to the publication of the full data set which we believe continues to underscore the clinical value of our miRview mets2 assay in identifying the primary tumor type in CUP patients in order to optimize treatment protocols and potentially improve clinical outcomes.

Kenneth A. Berlin, President and CEO of Rosetta Genomics

ROSG shares gained 15% as of 12pm EST, down 10% from the high of the day at $5.98 per share